Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial

RCT (n=342) found that oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization vs placebo (0.45 vs 0.38 events per person year respectively, HR 1.2, 95%CI 0.9-1.6).

Source:

Journal of the American Dental Association